Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Caterpillar Inc (CAT) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Caterpillar IncTrade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

Caterpillar Inc vs IDEXX Laboratories, Inc. — how do they compare? Caterpillar Inc trades at $867.2 (market cap $387.68B), while IDEXX Laboratories, Inc. trades at $572.59 (market cap $46.22B). The key difference: Caterpillar Inc is far larger — about 8.4× IDEXX Laboratories, Inc.'s market cap, and Caterpillar Inc pays a 0.77% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.

CATIDXX
Market Cap
$387.68B$46.22B
Sector
IndustrialsHealth
52-Week High
$1.06K$766.68
52-Week Low
$407.79$526.44
Enterprise Value
$426.11B$47.12B
Dividend Yield
0.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Caterpillar Inc

Caterpillar (CAT) trades at $837.58, down 0.55% on the day, with a bearish technical signal but strong fundamental performance. Recent quarters have consistently beaten EPS estimates, with Q2 2026 EPS of $8.17 surpassing the $6.22 expectation. Revenue growth is supported by AI data center demand, contributing to a robust $67.59B in 2025 revenue. The stock is near key support at $831, with resistance at $850.

Outlook remains positive due to strong earnings momentum and AI-driven infrastructure demand, though elevated valuation ratios (P/E of 36.32) pose a risk. Analyst consensus is bullish with a $1,010 price target, but investors should monitor macroeconomic pressures and competitive threats. The dividend history and cash flow stability add defensive appeal.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.

The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Caterpillar Inc

Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.

Read more on CAT

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX